Acute kidney disease and acute kidney injury biomarkers in coronary care unit patients

BMC Nephrology

Table 3 Calibration and discrimination of the AKI biomarkers in predicting AKD and 5-year mortality

	Calibration			Discrimination
	Goodness –of-fit (χ2)	df	p-value	AUROC±SE	95%CI	p-value
*For AKD prediction*
Serum IL-18	10.518	8	0.231	0.698 ± 0.033	0.634–0.762	< 0.001
Serum NGAL	5.756	8	0.675	0.630 ± 0.034	0.563–0.697	< 0.001
Urine NGAL	12.980	8	0.113	0.660 ± 0.036	0.591–0.730	< 0.001
Serum CysC	9.448	8	0.306	0.663 ± 0.033	0.598–0.728	< 0.001
*For 5-year mortality prediction*
Serum IL-18	0.712	8	0.999	0.522 ± 0.048	0.429–0.616	0.635
Serum NGAL	9.717	8	0.285	0.573 ± 0.047	0.482–0.665	0.113
Urine NGAL	19.266	8	0.014	0.712 ± 0.047	0.620–0.803	< 0.001
Serum CysC	7.780	8	0.455	0.554 ± 0.048	0.460–0.648	0.241

No statistically significant AUROC differences between serum IL-18, serum NGAL, urine NGAL and serum CysC for AKD prediction*.
Statistically significant AUROC differences between urine NGAL vs. serum IL-18, serum NGAL and serum CysC for 5-year mortality prediction, all p-values < 0.01*.
AKI Acute kidney injury, AKD Acute kidney disease, IL-18 Interleukin 18, NGAL Neutrophil gelatinase-associated lipocalin, CysC Cystatin C, AUROC Area under the receiver operating characteristic curve
*Pairwise comparisons of ROC curves, by Delong method, 1988

ISSN: 1471-2369